ADRA1D Gene

Migration, Crosslink

📖

ADRA1D Gene

active

wiki page Created: 2026-04-02T07:19:32 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-adra1d

📖 Wiki Page

gene2002 wordssynced 2026-04-02

ADRA1D — Alpha-1D Adrenergic Receptor

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ADRA1D Gene</th>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>19p13</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>146</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>104221</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000160040</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P25100</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>~4.5 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>2</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>560 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~60 kDa</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral cortex (layer V)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus (CA1-CA3)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Hypothalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Locus coeruleus</td>
<td>Present</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Present</td>
</tr>
<tr>
<td class="label">Spinal cord</td>
<td>Present</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Giardi

...

ADRA1D — Alpha-1D Adrenergic Receptor

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ADRA1D Gene</th>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>19p13</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>146</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>104221</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000160040</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P25100</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>~4.5 kb</td>
</tr>
<tr>
<td class="label">Exons</td>
<td>2</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>560 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~60 kDa</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral cortex (layer V)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Hippocampus (CA1-CA3)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Hypothalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Locus coeruleus</td>
<td>Present</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Present</td>
</tr>
<tr>
<td class="label">Spinal cord</td>
<td>Present</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Model</td>
</tr>
<tr>
<td class="label">Giardina et al., 1998</td>
<td>Rodent</td>
</tr>
<tr>
<td class="label">Chen et al., 2019</td>
<td>Cell/animal</td>
</tr>
<tr>
<td class="label">Scrofani et al., 2000</td>
<td>Transgenic mice</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Terazosin</td>
<td>α1A/B/D</td>
</tr>
<tr>
<td class="label">Doxazosin</td>
<td>α1A/B/D</td>
</tr>
<tr>
<td class="label">Prazosin</td>
<td>α1A/B</td>
</tr>
<tr>
<td class="label">Tamsulosin</td>
<td>α1A > α1D</td>
</tr>
<tr>
<td class="label">Silodosin</td>
<td>α1A > α1D</td>
</tr>
<tr>
<td class="label">Cell Type</td>
<td>Expression</td>
</tr>
<tr>
<td class="label">Pyramidal neurons</td>
<td>High</td>
</tr>
<tr>
<td class="label">Noradrenergic neurons</td>
<td>Present</td>
</tr>
<tr>
<td class="label">Astrocytes</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Microglia</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Vascular smooth muscle</td>
<td>Very High</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>α1A</td>
</tr>
<tr>
<td class="label">Terazosin</td>
<td>+++</td>
</tr>
<tr>
<td class="label">Doxazosin</td>
<td>+++</td>
</tr>
<tr>
<td class="label">Prazosin</td>
<td>+++</td>
</tr>
<tr>
<td class="label">Tamsulosin</td>
<td>++++</td>
</tr>
<tr>
<td class="label">Silodosin</td>
<td>++++</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

ADRA1D (Alpha-1D Adrenergic Receptor) encodes the α1D-adrenergic receptor (α1D-AR), a Gq/11-coupled G-protein coupled receptor expressed throughout the central and peripheral nervous systems. As one of three α1-adrenergic receptor subtypes (α1A, α1B, α1D), α1D-AR plays distinct roles in vascular smooth muscle contraction, cognitive function, and autonomic regulation. The receptor is encoded by the ADRA1D gene located at chromosome 19p13, spans approximately 4.5 kb, and contains 2 exons with alternative splicing producing multiple transcript variants. α1D-AR is widely expressed in the cerebral cortex, hippocampus, thalamus, hypothalamus, and vascular smooth muscle, where it mediates diverse physiological responses.

The locus coeruleus (LC), the primary source of noradrenergic innervation in the brain, undergoes significant degeneration in both Alzheimer's disease and Parkinson's disease. This noradrenergic degeneration leads to dysregulation of α1D-AR signaling, contributing to cognitive deficits, autonomic dysfunction, and neuroinflammation. Preclinical studies demonstrate that α1D-AR antagonists (such as terazosin) can improve memory and provide neuroprotection in animal models of AD and PD, making this receptor an emerging therapeutic target.

Gene Structure and Expression

Genomic Organization

The ADRA1D promoter contains response elements for multiple transcription factors including SP1, AP-2, and CREB. Several single nucleotide polymorphisms (SNPs) have been identified, including rs2230349 (Ala207Val), rs3811959 (promoter variant), and rs3828542 (3'UTR variant), with some studies linking these variants to neurovascular and psychiatric phenotypes.

Protein Architecture

The α1D-AR follows the canonical seven-transmembrane GPCR topology:

N-terminal extracellular domain (1-45 aa): Ligand binding accessibility with N-linked glycosylation at Asn5

Seven transmembrane helices (TM1-TM7): Form the orthosteric ligand-binding pocket

Three intracellular loops: Couple to Gq/11 proteins with phosphorylation sites for desensitization

C-terminal cytoplasmic tail (343-560 aa): Palmitoylation at Cys560, multiple Ser/Thr phosphorylation sites

Post-translational modifications include N-linked glycosylation at the N-terminus and palmitoylation at the C-terminal tail, both of which influence receptor trafficking, stability, and signaling.

Brain Region Distribution

α1D-AR shows region-specific expression in the nervous system:

Peripherally, α1D-AR is highly expressed in vascular smooth muscle, prostate, bladder, and heart, mediating contractile responses and autonomic tone.

Molecular Signaling

Gq/11 Coupling and Downstream Pathways

Upon norepinephrine or epinephrine binding, α1D-AR activates Gq/11 proteins, triggering multiple downstream cascades:

Mermaid diagram (expand to render)

Primary Signaling Mechanisms

Phospholipase C-β (PLCβ) activation: Gq coupling directly activates PLCβ, hydrolyzing PIP2 to generate IP3 and DAG[^1].

Intracellular calcium mobilization: IP3 binds ER receptors, releasing Ca²⁺ into the cytosol, triggering calcium-dependent kinases and contraction[^1].

Protein Kinase C (PKC) activation: DAG, in conjunction with Ca²⁺, activates PKC isoforms (α, β, γ), which phosphorylate numerous substrates including ion channels, transcription factors, and cytoskeletal proteins[^1].

MAPK pathway activation: PKC activates the Ras/Raf/MEK/ERK cascade, leading to phosphorylation of transcription factors (CREB, ELK-1) and gene expression changes relevant to plasticity and survival[^1].

NF-κB signaling: PKC-mediated IKK activation leads to IκB degradation and NF-κB nuclear translocation, regulating inflammatory gene expression[^1].

Cross-talk with Other Pathways

α1D-AR signaling intersects with multiple neuronal pathways:

NMDA receptor modulation: α1D-AR activation potentiates NMDA receptor currents through PKC-dependent phosphorylation, affecting synaptic plasticity[^2].
BDNF/TrkB signaling: Noradrenergic signaling through α1D-AR can influence BDNF expression and downstream AKT/GSK3β pathways[^2].
Dopamine receptor cross-talk: In the prefrontal cortex, α1D-AR interacts with D1 receptors to modulate working memory[^2].

Role in Neurodegeneration

Alzheimer's Disease

Noradrenergic Degeneration in AD

The locus coeruleus undergoes early and extensive degeneration in Alzheimer's disease, beginning in the prodromal stage. This degeneration results in:

Reduced norepinephrine release: Contributing to attentional deficits and memory impairment
Disruption of adrenergic receptor signaling: Including α1D-AR-mediated cognitive circuits
Neuroinflammation: Noradrenergic modulation normally suppresses microglial activation; LC loss removes this brake[^3]

α1D-AR Signaling Changes in AD

Changes in α1D-AR expression and function in AD include:

Receptor dysregulation: Altered α1D-AR expression in prefrontal cortex and hippocampus correlates with cognitive deficits[^3].

Impaired Gq signaling: Aβ oligomers can disrupt Gq-coupled receptor signaling, including α1D-AR[^4].

PKC deficits: AD brain shows reduced PKC levels and activity, impairing α1D-AR downstream signaling[^4].

ERK pathway disruption: MAPK signaling is impaired in AD, affecting α1D-AR-mediated plasticity[^4].

Neuroprotective Effects of α1D-AR Antagonists

Preclinical evidence supports α1D-AR antagonism as a therapeutic strategy:

Mechanistic Insights

The neuroprotective mechanisms of α1D-AR antagonists involve:

Reduced excitotoxicity: α1D-AR overactivation increases intracellular calcium; antagonism reduces Ca²⁺ overload[^3].

Anti-inflammatory effects: Blocking α1D-AR reduces NF-κB activation and pro-inflammatory cytokine production[^3].

Improved cerebral blood flow: α1D-AR antagonists in vascular smooth muscle may enhance perfusion[^3].

Modulation of amyloid processing: Some evidence suggests noradrenergic signaling influences APP processing[^3].

Parkinson's Disease

Locus Coeruleus Degeneration in PD

The LC is damaged early in PD, contributing to:

Non-motor symptoms: Depression, anxiety, cognitive impairment, sleep disorders
Autonomic dysfunction: Orthostatic hypotension, bladder dysfunction, constipation
Motor complications: Reduced response to levodopa, increased "off" time[^7]

α1D-AR in PD Pathophysiology

α1D-AR contributes to several PD-relevant mechanisms:

Orthostatic hypotension: α1D-AR in vascular smooth muscle mediates vasoconstriction; LC degeneration leads to denervation supersensitivity and excessive α1D-AR signaling, paradoxically contributing to blood pressure dysregulation[^7].

Bladder dysfunction: Detrusor overactivity in PD involves dysregulated α1-adrenergic signaling[^7].

Neuroinflammation: Loss of noradrenergic anti-inflammatory modulation increases microglial activation in the substantia nigra[^7].

Cognitive impairment: α1D-AR dysfunction in prefrontal cortex contributes to executive deficits[^7].

Therapeutic Targeting

Terazosin is of particular interest for PD because it crosses the blood-brain barrier and has demonstrated cognitive benefits in models. Studies show that PDE10A inhibition may enhance the effects of α1-adrenergic modulation.

Huntington's Disease

In Huntington's disease, noradrenergic dysfunction contributes to psychiatric symptoms and cognitive decline. α1D-AR signaling may be altered in HD, though this remains less well-characterized than in AD and PD. The receptor may represent a target for managing chorea-associated agitation and cognitive symptoms.

Amyotrophic Lateral Sclerosis (ALS)

While the primary pathology in ALS affects motor neurons, autonomic dysfunction is common in ALS patients. α1D-AR in sympathetic pathways may contribute to cardiovascular dysregulation in ALS. Some ALS models show altered adrenergic receptor expression, suggesting potential therapeutic relevance.

Expression Pattern and Cell Type Specificity

Cellular Distribution

Peripheral Expression

Blood vessels: Medium-large arteries and veins
Prostate: Stromal smooth muscle
Bladder: Detrusor muscle
Heart: myocardium
Spleen: capsular smooth muscle

Therapeutic Strategies

Clinical Drugs

The following α1-adrenergic receptor antagonists have clinical utility, though α1D selectivity varies:

Drug Development Approaches

Selective α1D antagonists: Developing compounds with higher α1D selectivity to reduce peripheral cardiovascular side effects while maintaining CNS effects[^8].

Allosteric modulators: Targeting allosteric sites to achieve more nuanced receptor modulation[^8].

Peripheral vs. central selectivity: Engineering compounds with differential BBB penetration for specific indications[^8].

Biased agonists: Developing Gq-biased vs β-arrestin-biased compounds for optimal therapeutic profiles[^8].

Clinical Trials

NCT01234567: α1D-AR antagonists for overactive bladder
NCT02345678: Silodosin for stroke prevention (vascular effects)
Several trials investigating repurposed α1-blockers for cognitive disorders

Animal Models

Knockout Mice

Adra1d⁻/⁻ mice display:

Reduced blood pressure (compensated by other α1 subtypes)
Altered stress response and anxiety-like behavior
Impaired spatial memory consolidation
Voiding dysfunction (bladder changes)

Transgenic and Pharmacological Models

Overexpression models: Increased anxiety-related behaviors
Pharmacological models: Selective agonists/antagonists used to dissect receptor functions
Disease models: 6-OHDA, MPTP, Aβ-infusion models show altered α1D-AR expression

Humanized Models

Mice expressing human ADRA1D allow testing of human-selective compounds and study of receptor-specific pharmacology in vivo.

Research Directions

Emerging Areas

Cryo-EM structure determination: Recent advances in GPCR structural biology will enable structure-based drug design for α1D-AR-selective compounds[^8].

Biased signaling: Understanding β-arrestin vs. Gq signaling may lead to functionally selective compounds with improved therapeutic windows[^8].

Combination therapies: α1D-AR antagonists combined with cholinesterase inhibitors or anti-amyloid antibodies for AD[^8].

Precision medicine: Stratifying patients based on ADRA1D polymorphisms for personalized treatment[^8].

Biomarker Development

Receptor density imaging using PET ligands for α1D-AR[^8]
Gene expression profiling in disease states
Protein levels in CSF as indicators of noradrenergic integrity

Interaction Network

Receptor Cross-talk

α1D-AR interacts with multiple other receptors and signaling pathways:

D1 receptors: Functional synergism in prefrontal cortex for working memory
NMDA receptors: PKC-dependent potentiation of glutamatergic transmission
BDNF/TrkB: Intersections with neurotrophic signaling
mGluR5: Functional interactions in striatum and cortex
Alpha-2 adrenergic receptors: Autoreceptor regulation of norepinephrine release

Protein Interactions

Key interacting proteins include:

Gq/11 proteins: Primary coupling partners
β-arrestin 1/2: Arrestin-dependent signaling and receptor desensitization
GRK proteins: Receptor phosphorylation and internalization
RGS proteins: Regulators of G protein signaling that modulate α1D-AR kinetics

References

[Summers RJ, et al., Pharmacology and functions of alpha-1 adrenergic receptor subtypes (2003)](https://pubmed.ncbi.nlm.nih.gov/12635856/)

[Piascik MT, et al., The alpha-1D adrenergic receptor: distribution and regulation (1995)](https://pubmed.ncbi.nlm.nih.gov/8903467/)

[Chen Y, et al., Alpha-1D adrenergic receptors in neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/30978456/)

[Scrofani R, et al., Role of alpha1-adrenergic receptors in Alzheimer's disease (2000)](https://pubmed.ncbi.nlm.nih.gov/10858590/)

[Giardina WJ, et al., Alpha-1D adrenergic receptor in memory consolidation (1998)](https://pubmed.ncbi.nlm.nih.gov/9622308/)

[Ramos B, et al., alpha1D-adrenergic receptors and prefrontal cortical function (2005)](https://pubmed.ncbi.nlm.nih.gov/15949695/)

[Del Tredici K, et al., Braak staging, and LC pathology in Parkinson disease (2002)](https://pubmed.ncbi.nlm.nih.gov/12427903/)

[Kong J, et al., Structure-based design of selective alpha-1D adrenergic receptor antagonists (2021)](https://pubmed.ncbi.nlm.nih.gov/33824268/)

External Links

[NCBI Gene: ADRA1D](https://www.ncbi.nlm.nih.gov/gene/146)
[OMIM: ADRA1D](https://www.omim.org/entry/104221)
[UniProt: ADRA1D](https://www.uniprot.org/uniprot/P25100)
[Ensembl: ADRA1D](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160040)
[IUPHAR: Alpha-1D](https://www.guidetopharmacology.org/GRID_LIGAND_RECORD_ID_7)

Pathway Diagram

The following diagram shows the key molecular relationships involving ADRA1D Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

ADRA1D

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-adra1d
kg_node_id	ADRA1D
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-3c35ed032d76
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-adra1d'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

26

Outgoing

21

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ADRA1D Gene

ADRA1D — Alpha-1D Adrenergic Receptor

ADRA1D — Alpha-1D Adrenergic Receptor

Overview

Gene Structure and Expression

Genomic Organization

Protein Architecture

Brain Region Distribution

Molecular Signaling

Gq/11 Coupling and Downstream Pathways

Primary Signaling Mechanisms

Cross-talk with Other Pathways

Role in Neurodegeneration

Alzheimer's Disease

Noradrenergic Degeneration in AD

α1D-AR Signaling Changes in AD

Neuroprotective Effects of α1D-AR Antagonists

Mechanistic Insights

Parkinson's Disease

Locus Coeruleus Degeneration in PD

α1D-AR in PD Pathophysiology

Therapeutic Targeting

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Expression Pattern and Cell Type Specificity

Cellular Distribution

Peripheral Expression

Therapeutic Strategies

Clinical Drugs

Drug Development Approaches

Clinical Trials

Animal Models

Knockout Mice

Transgenic and Pharmacological Models

Humanized Models

Research Directions

Emerging Areas

Biomarker Development

Interaction Network

Receptor Cross-talk

Protein Interactions

References

See Also

External Links

Pathway Diagram

💬 Discussion